Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
Go back to Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 57.04 -1.03 (1.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.07 | 52 Week High | $0.52 | |||
| Open | $57.20 | 52 Week Low | $0.08 | |||
| Day High | $58.43 | P/E | N/A | |||
| Day Low | $56.62 | EPS | $-3.80 | |||
| Volume | 2,161,213 | |||||
